HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
An expert still believes in Tempest Therapeutics, but thinks it's worth less money now. When experts lower their price targets, watch if the company is facing new challenges or just changing their mind about the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.